Acute lymphoblastic leukaemia develops in both children and adults, with a peak incidence
between 1 year and 4 years. Most acute lymphoblastic leukaemia arises in healthy …

Importance With the advent of potent BCR:: ABL1 tyrosine kinase inhibitors (TKIs),
Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL) is now …

The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of
ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk …

Background Outcomes in patients with Philadelphia chromosome (Ph)–positive acute
lymphoblastic leukemia (ALL) have improved with the use of tyrosine kinase inhibitors …

The estimated overall incidence of acute lymphoblastic leukaemia (ALL) and lymphoblastic
lymphoma in Europe is 1.28 per 100 000 individuals annually, with significant age-related …

In this study, we randomly compared high doses of the tyrosine kinase inhibitor imatinib
combined with reduced-intensity chemotherapy (arm A) to standard imatinib/hyperCVAD …

Acute lymphoblastic leukaemia, a malignant disorder of lymphoid progenitor cells, affects
both children and adults, with peak prevalence between the ages of 2 and 5 years. Steady …

The Philadelphia chromosome positive arm of the UKALLXII/ECOG2993 study for adult
acute lymphoblastic leukemia (ALL) enrolled 266 patients between 1993 and 2003 (pre …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned …

Although acute lymphoblastic leukemia is curable in one third of adult patients, results vary
greatly on account of different clinical, immunologic, and cytogenetic/genetic characteristics …